709 related articles for article (PubMed ID: 7971242)
21. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration.
Antiplatelet Trialists' Collaboration
Br Med J (Clin Res Ed); 1988 Jan; 296(6618):320-31. PubMed ID: 3125883
[TBL] [Abstract][Full Text] [Related]
22. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
De Schryver EL; Algra A; van Gijn J
Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
[TBL] [Abstract][Full Text] [Related]
23. Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin.
McGrath E; O'Conghaile A; Eikelboom JW; Dinneen SF; Oczkowski C; O'Donnell MJ
Cerebrovasc Dis; 2011; 32(1):22-7. PubMed ID: 21576939
[TBL] [Abstract][Full Text] [Related]
24. Ticlopidine: a new antiplatelet agent for cerebrovascular disease.
Robert S; Miller AJ; Fagan SC
Pharmacotherapy; 1991; 11(4):317-22; discussion 322-5. PubMed ID: 1923914
[TBL] [Abstract][Full Text] [Related]
25. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
[TBL] [Abstract][Full Text] [Related]
26. Antiplatelet therapy in the prevention of stroke.
Easton JD
Drugs; 1991; 42 Suppl 5():39-50. PubMed ID: 1726215
[TBL] [Abstract][Full Text] [Related]
27. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
[TBL] [Abstract][Full Text] [Related]
28. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Jamieson DG; Parekh A; Ezekowitz MD
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
[TBL] [Abstract][Full Text] [Related]
29. Antiplatelet and antithrombotic treatment of patients with peripheral arterial disease.
Poredos P; Jezovnik MK
Int Angiol; 2010 Feb; 29(1):20-6. PubMed ID: 20224527
[TBL] [Abstract][Full Text] [Related]
30. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
; Anand S; Yusuf S; Xie C; Pogue J; Eikelboom J; Budaj A; Sussex B; Liu L; Guzman R; Cina C; Crowell R; Keltai M; Gosselin G
N Engl J Med; 2007 Jul; 357(3):217-27. PubMed ID: 17634457
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of efficacy and safety of antiplatelet therapy in cardiovascular and cerebrovascular disease.
Gebel JM
Am J Cardiovasc Drugs; 2010; 10(2):115-24. PubMed ID: 20334449
[TBL] [Abstract][Full Text] [Related]
32. Antiplatelet drugs in ischemic stroke prevention: from monotherapy to combined treatment.
Urbano LA; Bogousslavsky J
Cerebrovasc Dis; 2004; 17 Suppl 1():74-80. PubMed ID: 14694284
[TBL] [Abstract][Full Text] [Related]
33. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
Diener HC; Bogousslavsky J; Brass LM; Cimminiello C; Csiba L; Kaste M; Leys D; Matias-Guiu J; Rupprecht HJ
Cerebrovasc Dis; 2004; 17(2-3):253-61. PubMed ID: 14981346
[TBL] [Abstract][Full Text] [Related]
34. [Antithrombotic therapy after cerebral ischemia].
Schellinger PD; Orberk E; Hacke W
Fortschr Neurol Psychiatr; 1997 Sep; 65(9):425-34. PubMed ID: 9417427
[TBL] [Abstract][Full Text] [Related]
35. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
Aronow WS
Drugs Aging; 1999 Aug; 15(2):91-101. PubMed ID: 10495069
[TBL] [Abstract][Full Text] [Related]
36. Antiplatelet agents and stroke prevention.
Dyken ML
Semin Neurol; 1998; 18(4):441-50. PubMed ID: 9932615
[TBL] [Abstract][Full Text] [Related]
37. [Anti-platelet drugs (aspirin, ticlopidine, etc)].
Ikeda U
Nihon Rinsho; 2006 Apr; 64(4):743-7. PubMed ID: 16613193
[TBL] [Abstract][Full Text] [Related]
38. Antiplatelets and stroke outcomes: state of the science.
Meyer D
Crit Care Nurs Clin North Am; 2009 Dec; 21(4):517-28. PubMed ID: 19951767
[TBL] [Abstract][Full Text] [Related]
39. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.
Hass WK; Easton JD; Adams HP; Pryse-Phillips W; Molony BA; Anderson S; Kamm B
N Engl J Med; 1989 Aug; 321(8):501-7. PubMed ID: 2761587
[TBL] [Abstract][Full Text] [Related]
40. [The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review].
Schellinger PD; Jüttler E; Meyding-Lamadé UK; Schwark C
Fortschr Neurol Psychiatr; 2004 May; 72(5):270-81. PubMed ID: 15136948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
